Awards & Advancement

NIH Director’s high-risk research awards announced for 2017

Tuesday, October 10, 2017

The NIH’s High-Risk, High-Reward Research program, part of the NIH Common Fund, funded 86 awards to exceptionally creative scientists proposing to use highly innovative approaches to tackle major challenges in biomedical research. The program supports high-risk ideas with high-impact potential, such as recording the history of an individual cell in its DNA for future playback; understanding how bacteria in the microbiome can share anti-drug-resistance genes among themselves; resetting the immune system to allow universal organ transplants; and reimagining clinical trials to make them more personalized and more effective.

[Read More]

Research!America announces 2018 Advocacy Awards Honorees

Friday, October 6, 2017

A former congressional leader who was instrumental in doubling the NIH budget, the head of a global research center aimed at reducing the burden of disease, two long-time mental health advocates dedicated to accelerating research, a rare disease organization committed to biotech innovation, and a world-renowned vaccine researcher are among those who will be honored at Research!America’s 22nd annual Advocacy Awards on Wednesday, March 14, 2018, in Washington, D.C. The honorees for the Isadore Rosenfeld Award for Impact on Public Opinion and the Edwin C. Whitehead Award for Medical Research Advocacy will be announced in the coming weeks.

[Read More]

AMRI names Joseph D. Sangregorio SVP and chief human resources officer

Tuesday, October 3, 2017

AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, announced that Joseph D. Sangregorio has joined the company as senior vice president, chief human resources officer (CHRO), overseeing all HR management and human capital strategies at AMRI.

[Read More]

Dixie-Lee Esseltine joins HBS Kraft Precision Medicine Accelerator

Friday, September 29, 2017

Dr. Dixie-Lee Esseltine, formerly the Vice President of Global Clinical Development at Takeda Pharmaceuticals, recently joined the Harvard Business School’s (HBS) Kraft Precision Medicine Accelerator. Esseltine will lead the Accelerator’s Clinical Trials work stream, which is comprised of leading nonprofit organizations (NPOs) and clinical leaders focused on precision medicine. The goal of this work stream is to accelerate the advancement of innovative platform trials across cancers by identifying best practices and sharing knowledge, helping NPOs build their understanding of the design and operation of master protocols, and working with the FDA to improve master protocols.

[Read More]